Talidomida, peginterferón alfa-2b y ribavirina en el tratamiento de pacientes no respondedores con hepatitis crónica C genotipo 1: estudio piloto

Pardo-Yules, Benjamín; Gallego-Durán, Rocío; Eslam, Mohammed; García-Collado, Carlos; Grande, Lourdes; Paradas, Carmen; Morillo, Ramón; Dorantes, Benito; Romero-Gómez, Manuel.
Rev. esp. enferm. dig ; 103(12): 619-625, dic. 2011. tab, ilus
Artículo en Español | IBECS (España) | ID: ibc-93795

Documentos relacionados

  1. IP<sub>3</sub>R1-mediated MAMs formation contributes to mechanical trauma-induced hepatic injury and the protective effect of melatonin.
  2. Prediction of biochemical nonresolution in patients with chronic drug-induced liver injury: A large multicenter study.
  3. Assessing the mechanisms and adjunctive therapy for arsenic-induced liver injury in rats.
  4. Humoral mechanisms regulating the functions of progenitor cells in chronic hepatitis.
  5. Inflammation-associated suppression of metabolic gene networks in acute and chronic liver disease.
  6. Mechanisms of hepatoprotective effect of immobilized granulocyte colony-stimulating factor.
  7. Characterization of Immature Myofibroblasts of Stellate Cell or Mesenchymal Cell Origin in D-Galactosamine-Induced Liver Injury in Rats.
  8. In Silico Analysis Identifies the Anti-Liver Injury Targets of Diammonium Glycyrrhizinate: Validated in Perfluorooctanoic Acid-Lesioned Mouse Model.
  9. Antitubercular drugs induced liver injury: an updated insight into molecular mechanisms.
  10. Corticosteroid-Induced Liver Injury in Adult-Onset Still's Disease.